Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignt Glioma - Overview
Recurrent Malignt Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignt Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignt Glioma - Companies Involved in Therapeutics Development
Recurrent Malignt Glioma - Drug Profiles
Recurrent Malignt Glioma - Dormant Projects
Recurrent Malignt Glioma - Discontinued Products
Recurrent Malignt Glioma - Product Development Milestones
Featured News & Press Releases
Apr 21, 2017: Japan’s Ministry of Health, Labour and Welfare Announces SAKIGAKE Desigtion For Stella Pharma’s Cancer Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Recurrent Malignant Glioma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Recurrent Malignant Glioma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Recurrent Malignant Glioma - Pipeline by Candel Therapeutics Inc, 2021
Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2021
Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, 2021
Recurrent Malignant Glioma - Pipeline by InSight Biopharmaceuticals Ltd (Inactive), 2021
Recurrent Malignant Glioma - Pipeline by Oblato Inc, 2021
Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, 2021
Recurrent Malignant Glioma - Pipeline by Smerud Medical Research International AS, 2021
Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, 2021
Recurrent Malignant Glioma - Dormant Projects, 2021
Recurrent Malignant Glioma - Dormant Projects, 2021 (Contd..1)
Recurrent Malignant Glioma - Discontinued Products, 2021